title: Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
abstract: Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.
authors.affiliation: Dept of Immunotechnology, Lund University, Sweden.
authors.forename: C K
authors.initials: CK
authors.lastname: Borrebaeck
authors.forename: A C
authors.initials: AC
authors.lastname: Malmborg
authors.forename: M
authors.initials: M
authors.lastname: Ohlin
mesh_terms: D000818:Animals; D000910:Antibodies, Heterophile / Q000097:blood; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D002240:Carbohydrate Sequence; D004187:Disaccharides / Q000737:chemistry / Q000276:immunology; D006031:Glycosylation; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D004187:Disaccharides; C055075:galactosyl-(1-3)galactose